Heather K. Raymon

2.6k citations

44 papers · 1.7k indexed · h-index 21

Impact in

Developmental Neuroscience top 2%
- Neurogenesis and neuroplasticity mechanisms
Cellular and Molecular Neuroscience top 5%
- Nerve injury and regeneration
- Neuroscience and Neuropharmacology Research
- Nuclear Receptors and Signaling

Papers in

Developmental Neuroscience 4
- Neurogenesis and neuroplasticity mechanisms 4
Cellular and Molecular Neuroscience 13
- Nerve injury and regeneration 7

Co-authors: Patrik Brundin Cecilia Lundberg Julie Lotharius Sebastian Barg Ron S. Broide Ursula H. Winzer‐SerhanY ChenF.M. Leslie
Journals: Blood (6 papers)Cancer Research (4 papers)European Journal of Cancer (4 papers)Molecular Cancer Therapeutics (2 papers)Experimental Neurology (2 papers)
Partner nations: United States Switzerland Sweden

In The Last Decade

Heather K. Raymon

43 papers receiving 1.6k citations

Peers

Countries citing papers authored by Heather K. Raymon

Since Specialization

Citations

This map shows the geographic impact of Heather K. Raymon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather K. Raymon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather K. Raymon more than expected).

Fields of papers citing papers by Heather K. Raymon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather K. Raymon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather K. Raymon. The network helps show where Heather K. Raymon may publish in the future.

Co-authors

The 25 scholars most cited alongside Heather K. Raymon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Heather K. Raymon Line = papers co-authored together Heather K. Raymon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study Blood ·Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, Jasmine R. Cloud, 袁以洋, Francisco Bernardo Perez Orozco, Thorsten Graef, Heather K. Raymon, Alison J. Moskowitz	2024	2
2	Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes Annals of Hematology ·Amer M. Zeidan, Daniel J. DeAngelo, Jeanne Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei, Heather K. Raymon, Andrea Bonomi, FENG-KUI LUAN, Jan Philipp Bewersdorf, Michael R. Burgess, Kristen Hege, Wendy Stock	2022	66
3	Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody Cancer Immunology Immunotherapy ·Rama Krishna Narla, Hardik Modi, Daniel E. Bauer, Mahan Abbasian, Jim Leisten, Joseph R. Piccotti, FENG-KUI LUAN, Brendan P. Eckelman, Quinn L. Deveraux, John C. Timmer, Dan Zhu, Lilly Wong, Paúl Ismael Sigüenza Garzón, Heather K. Raymon, Kandasamy Hariharan	2021	29
4	First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy SHILAP Revista de lepidopterología ·Pamela N. Münster, Monica Mita, Amit Mahipal, John Nemunaitis, Christophe Massard, Tom Mikkelsen, Cristina Cruz, Luis Paz‐Ares, Manuel Hidalgo, Dana E. Rathkopf, E. van Sebille, Yunus Helmi, Barbara Eichhorst, Timothy F. Cloughesy, P. M. Sheery, Li S, Heather K. Raymon, Álvaro Fernando Quinde Ortiz, Kristen Hege, Brigitte Boothe	2019	1
5	<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p> Cancer Management and Research ·Pamela N. Münster, Monica Mita, Amit Mahipal, John Nemunaitis, Christophe Massard, Tom Mikkelsen, Cristina Cruz, Luis Paz‐Ares, Manuel Hidalgo, Dana E. Rathkopf, George Blumenschein, David C. Smith, Barbara Eichhorst, Tim Cloughesy, Ellen Filvaroff, Shaoyi Li, Heather K. Raymon, Gregory B Diette, Kristen Hege, Johanna C. Bendell	2019	67
6	Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint Molecular Cancer Therapeutics ·Dan Zhu, Shuichan Xu, Gordafaried Deyanat‐Yazdi, Gertrude Richardson, Leo A. Barnes, Rama Krishna Narla, Tam Tran, David Mikolon, Yuhong Ning, Tao Shi, Ning Jiang, Heather K. Raymon, Jennifer R. Riggs, John F. Boylan	2018	28
7	Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma British Journal of Haematology ·Emily Rychak, Derek Mendy, Tao Shi, Yuhong Ning, Jim Leisten, Ling Lu, Karen Miller, Rama Krishna Narla, Robert Z. Orlowski, Heather K. Raymon, Chad C. Bjorklund, Anjan Thakurta, Anita K. Gandhi, Brian E. Cathers, Rajesh Chopra, Thomas O. Daniel, Antonia Lopez‐Girona	2016	40
8	Abstract A165: Antitumor activity of mTOR kinase inhibitor CC-223 in a mouse model of prostate cancer. Molecular Cancer Therapeutics ·Rama Krishna Narla, Gertrude Richardson, S SHALABY, Jason D. Katz, Julius Apuy, Mehran F. Moghaddam, Kimberly E. Fultz, Sabita Sankar, Deborah S. Mortensen, Heather K. Raymon	2013	1
9	The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide Blood ·Emily Rychak, Derek Mendy, Karen Miller, Jim Leisten, Rama Krishna Narla, Heather K. Raymon, Rajesh Chopra, Antonia Lopez‐Girona	2013	1
10	1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4 Bioorganic & Medicinal Chemistry ·Alexander L. Ruchelman, Hon‐Wah Man, Roger Chen, Wei Liu, Ling Lu, 幹夫石丸, Ling Zhang, Jim Leisten, Kevin Dalla Torre, Rama Krishna Narla, Heather K. Raymon, George W. Muller	2011	22
11	Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line—Studies in vitro and after intracerebral grafting in vivo Molecular and Cellular Neuroscience ·Gesine Paul, Nicolaj S. Christophersen, Heather K. Raymon, D. Y.-M., Ruben Smith, Patrik Brundin	2007	26
12	Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line Journal of Biological Chemistry ·Julie Lotharius, Sebastian Barg, Jurusan Bud, Cecilia Lundberg, Heather K. Raymon, Patrik Brundin	2002	277
13	Application ofex VivoGene Therapy in the Treatment of Parkinson's Disease Experimental Neurology ·Heather K. Raymon, Silke Thode, Fred H. Gage	1997	38
14	Expression of α2 adrenoceptors during rat brain development—I. α2A messenger RNA expression Neuroscience ·Ursula H. Winzer‐Serhan, Heather K. Raymon, Ron S. Broide, Y Chen, F.M. Leslie	1996	104
15	Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease Nature Medicine ·Jo Tatchell, Jasodhara Ray, Heather K. Raymon, Andrew Baird, Joanna Hogg, Lisa J. Fisher, Fred H. Gage	1995	174
16	Regional Differences in Responsiveness of Adult CNS Axons to Grafts of Cells Expressing Human Neurotrophin 3 Experimental Neurology ·Nadine Lederer, Mark H. Tuszynski, Heather K. Raymon, Steven T. Suhr, William Stuart McRae Craig, Kevin R. Jones, Louis F. Reichardt, Fred H. Gage	1995	39
17	[2] Generation and culturing of precursor cells and neuroblasts from embryonic and adult central nervous system Methods in enzymology on CD-ROM/Methods in enzymology ·Jasodhara Ray, Heather K. Raymon, Fred H. Gage	1995	34
18	Opioid Effects on [³H]Norepinephrine Release from Dissociated Embryonic Locus Coeruleus Cell Cultures Journal of Neurochemistry ·Heather K. Raymon, Frances M. Leslie	1994	15
19	Cells Engineered to Produce Acetylcholine: Therapeutic Potential for Alzheimer's Disease^a Annals of the New York Academy of Sciences ·Lisa J. Fisher, Heather K. Raymon, Fred H. Gage	1993	19
20	Further pharmacological characterization of [3H]idazoxan binding sites in rat brain: evidence for predominant labeling ofα2-adrenergic receptors Brain Research ·Heather K. Raymon, Thressa Smith, Frances M. Leslie	1992	17

About Heather K. Raymon

Heather K. Raymon is a scholar working on Developmental Neuroscience, Cellular and Molecular Neuroscience, Immunology, Oncology and Hematology, having authored 44 papers that have together received 1.7k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (8 papers), Nerve injury and regeneration (7 papers), CAR-T cell therapy research (6 papers), Erythrocyte Function and Pathophysiology (5 papers), Receptor Mechanisms and Signaling (5 papers), Immune Cell Function and Interaction (4 papers), Phagocytosis and Immune Regulation (4 papers) and Neurogenesis and neuroplasticity mechanisms (4 papers). The work is most often cited by research in Developmental Neuroscience (220 citations), Cellular and Molecular Neuroscience (607 citations), Neurology (221 citations), Hematology (141 citations) and Genetics (130 citations). Heather K. Raymon has collaborated with scholars based in United States, Switzerland and Sweden. Frequent co-authors include Patrik Brundin, Cecilia Lundberg, Julie Lotharius, Sebastian Barg, Ron S. Broide, Ursula H. Winzer‐Serhan, Y Chen, F.M. Leslie, Jasodhara Ray and Fred H. Gage. Their work appears in journals such as Blood, Cancer Research, European Journal of Cancer, Molecular Cancer Therapeutics and Experimental Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact